Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Description

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)

Conditions

Idiopathic Inflammatory Myopathies

Talk to us

Study Overview

On this page

Study Details

Study overview

A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)

A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM)

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

Condition
Idiopathic Inflammatory Myopathies
Intervention / Treatment

-

Contacts and Locations

Iowa City

University Of Iowa, Iowa City, Iowa, United States, 52242

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Men and women, aged \>18 and ≤65 years, with a diagnosis of probable or definite myositis according to American College of Rheumatology/European League Against Rheumatism 2017 (ACR/EULAR 2017) criteria
  • 2. Participants who had inadequate response to prior therapy
  • 3. Diagnosed with active disease
  • 4. Participant must meet criteria for severe myositis
  • 1. Any condition during Screening that could prevent a complete washout of medications or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study
  • 2. BMI at Screening of ≤18.5 or ≥35 kg/m2
  • 3. Severe muscle damage at Screening
  • 4. Inadequate organ function
  • 5. Hypersensitivity and/or contraindications to any product (including its ingredients) to be given to the participant as per the study protocol
  • 6. Other inflammatory and non-inflammatory myopathies
  • 7. Any medical conditions that are not related to IIM that would jeopardize the ability of the participant to tolerate CD19 CAR-T cell therapy

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Novartis Pharmaceuticals,

Novartis Pharmaceuticals, STUDY_DIRECTOR, Novartis Pharmaceuticals

Study Record Dates

2030-06-01